Clinical trials: Afib
Atrial Fibrillation
aMAZE Trial Continued Access Protocol
aMAZE CAP is an extension to the current aMAZE Trial investigation (IDEG150107/NCT02517397/Protocol Appendix 16) in the form of a nested, non-randomized registry, to allow ongoing treatment of subjects and the collection of…
- Trial name
- aMAZE CAP (NCT04468334)
- Testing
- LARIAT + PVI
- Where
- 25 sites in United States
- Volunteers
- 82 people
- Sponsor
- AtriCure, Inc.
Paroxysmal Atrial Fibrillation (PAF)
A Clinical Study on the Use of a Domestically Produced Three-dimensional Cardiac Electrophysiological Mapping System Combined With Pressure Monitoring Technology and Star Mapping Technology for the Treatment of Paroxysmal Atrial Fibrillation.
Validating the safety and efficacy of pressure monitoring technology and star-shaped marking technology for the treatment of paroxysmal atrial fibrillation
- Trial name
- paroxysmal at (NCT07039032)
- Testing
- FireMagic™ Magbot Ablation Catheter 、FireMagic™ TrueForce™ Ablation Catheter
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shanghai MicroPort EP MedTech Co., Ltd.
Atrial Fibrillation
Study to Learn More About the Benefits and Side-effects of Drugs Rivaroxaban and Apixaban Compared to the Drug Warfarin for Stroke Prevention in Patients With Rapid and Irregular Heartbeat Which is Not Due to a Heart-valve Fault (Non-valvular Atrial Fibrillation) in the UK Routine Clinical Practice
This population-based study will identify patients with rapid and irregular heartbeat which is not due to a fault with the heart valves (non-valvular atrial fibrillation) who initiate rivaroxaban, apixaban or warfarin as…
- Trial name
- SiERRA UK (NCT03847181)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Warfarin
- Where
- United Kingdom
- Volunteers
- 45,164 people
- Sponsor
- Bayer
Atrial Tachycardia (Including Atrial Flutter) Post Atrial Fibrillation Ablation or Cardiac Surgery
Multi-center Complex Atrial Tachycardia High-Resolution Mapping Registry (MATH)
This study is an observational study without any hypothesis testing. It intended to observe the clinical application of electrophysiological mapping and catheter ablation of atrial tachycardia post atrial fibrillation ablation or…
- Trial name
- NCT03613831
- Testing
- patient who used Rhythmia system and Orion catheter
- Where
- China
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation
Study of Major Cardiovascular Events in Patients With Nonvalvular Atrial Fibrillation Treated With Rivaroxaban
Evaluation of the performance of the 2MACE index in a population of nonvalvular atrial fibrillation (NVAF) patients treated with rivaroxaban in Spain
- Trial name
- EMIR (NCT02975453)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 1,481 people
- Sponsor
- Bayer
Pulmonary Embolism (Diagnosis), Deep Vein Thrombosis
Microvisk Continuous Blood Donation Study
Microvisk Technologies Ltd designs and develops test systems for monitoring the effectiveness of Warfarin and Warfarin-like medications.
- Conditions
- Pulmonary Embolism (Diagnosis), Deep Vein Thrombosis, Atrial Fibrillation (AF)
- Trial name
- NCT06648837
- Testing
- Venepuncture, Collection of relevant information
- Where
- United Kingdom
- Volunteers
- 2,500 people
- Sponsor
- Microvisk Technologies Ltd
Atrial Fibrillation
Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia
The study aim to assess demographic and clinical characteristics , treatment patterns and as exploratory analysis will descriptively assess the time to clinical events of NVAF patients treated with oral anticoagulants (OACs) in…
- Trial name
- NCT04234698
- Where
- Colombia
- Volunteers
- 2,076 people
- Sponsor
- Pfizer
Atrial Fibrillation, Atrial Fibrillation, Persistent
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
Demonstrate the safety and effectiveness of the Ablacath™ Mapping Catheter and Ablamap® System in patients with all types of atrial fibrillation (AF) including paroxysmal or persistent or long-standing persistent, undergoing and…
- Conditions
- Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia
- Trial name
- RESOLVE-AF (NCT05883631)
- Testing
- Electrographic Flow (EGF) mapping and ablation of EGF-identified sources of Atrial Fibrillation, Electrographic Flow (EGF) mapping (no ablation)
- Where
- 24 sites in United States, Belgium and 2 more
- Volunteers
- 400 people
- Sponsor
- Cortex
Atrial Fibrillation
A Study For Treatment Of Paroxysmal Atrial Fibrillation (PAF) With The THERMOCOOL SMARTTOUCH SF Catheter and TRUPULSE Generator
The purpose of this study is to demonstrate safety and effectiveness of the ablation system (THERMOCOOL SMARTTOUCH SF [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in…
- Trial name
- SmartfIRE (NCT05752487)
- Testing
- Pulsed Field (PF) /Radiofrequency (RF) Catheter ablation
- Where
- 9 sites in Austria, Belgium and 2 more
- Volunteers
- 149 people
- Sponsor
- Biosense Webster, Inc.
Atrial Fibrillation Paroxysmal, Cardiac Ablation
CellFX® Nanosecond Pulsed Field Ablation (PFA) 360 Catheter Ablation System for Treatment of Atrial Fibrillation
The objective of this study is to demonstrate initial safety and effectiveness of the CellFX nano-second Pulsed Field Ablation (nsPFA or nano-PFA) 360 Catheter Endocardial Ablation System in treating subjects with atrial…
- Conditions
- Atrial Fibrillation Paroxysmal, Cardiac Ablation, Cardiac Arrhythmia
- Trial name
- NCT06696170
- Testing
- CellFX nano-pFA 360 Endocardial Ablation Catheter System
- Where
- 3 sites in Belgium, Czechia and 1 more
- Volunteers
- 60 people
- Sponsor
- Pulse Biosciences, Inc.
Scar-related Atrial Tachycardia, Paroxysmal Atrial Fibrillation
A Study Assessing Arrhythmia Mapping With the Multi-Electrode OPTRELL™ Mapping Catheter
The purpose of this study is to assess the performance and safety for the use of the OPTRELL Catheter for intracardiac mapping in the atria and ventricles.
- Conditions
- Scar-related Atrial Tachycardia, Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation, Tachycardia, Ventricular
- Trial name
- OPTIMUM (NCT04983797)
- Testing
- OPTRELL Mapping Catheter
- Where
- 3 sites in Belgium, Lithuania
- Volunteers
- 31 people
- Sponsor
- Biosense Webster, Inc.
Persistent Atrial Fibrillation
WATCHMAN for Concomitant Left Atrial Appendage Electrical Isolation and Occlusion to Treat Persistent Atrial Fibrillation Rhythm
WATCH-Rhythm is a prospective, randomized, multi-center, investigation to collect safety and effectiveness data on combining conventional AF ablation with LAA electric isolation and closure within a single procedure.
- Trial name
- WATCH-Rhythm (NCT03835338)
- Testing
- Pulmonary Vein Isolation, LAA Isolation, LAA Occlusion
- Sponsor
- Boston Scientific Corporation
Atrial Fibrillation
Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients
Vine™ is a permanent carotid filter designed to provide protection against embolic stroke in people with atrial fibrillation. It is implanted bilaterally in the common carotid arteries from a thin needle under ultrasound…
- Trial name
- CAPTURE (NCT03571789)
- Testing
- Vine™
- Where
- 4 sites in Belgium, Czechia and 1 more
- Volunteers
- 25 people
- Sponsor
- Javelin Medical
Atrial Fibrillation
Efficacy and Safety Study on Agilis NxT Introducer in AF Patients
To prove if the success rate of curative treatment of atrial fibrillation in left atrial circumferential pulmonary vein ablation is higher by using a steerable transseptal introducer giving access to the left atrium then by using…
- Trial name
- AGILIS (NCT00469638)
- Testing
- Left atrial catheter ablation guided by introducer using Agilis sheeth, Left atrial catheter ablation guided by introducer using Non-steerable sheeth
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Abbott Medical Devices
Atrial Fibrillation (AF)
Measuring Local Potentials in PFA. MULTI PFA (EU)
The study is a prospective, multi-center, exploratory, observational study with the ECGenius® System and the PFAnalyzer software module in PFA cases using the Affera Sphere 9, FaraWave, PulseSelect, Volt or VariPulse PFA systems.
- Trial name
- MULTI PFA (NCT07379697)
- Volunteers
- 30 people
- Sponsor
- CathVision ApS
Atrial Fibrillation, Percutaneous Coronary Intervention
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
The primary purpose of this study is to evaluate the safety for 2 different rivaroxaban treatment strategies and one Vitamin K Antagonist (VKA) treatment strategy utilizing various combinations of dual antiplatelet therapy (DAPT)…
- Trial name
- PIONEER AF-PCI (NCT01830543)
- Testing
- rivaroxaban 2.5 mg, rivaroxaban 15 mg, rivaroxaban 10 mg
- Where
- 348 sites in United States, Argentina and 23 more
- Volunteers
- 2,124 people
- Sponsor
- Janssen Scientific Affairs, LLC
Atrial Fibrillation (AF), Paroxysmal AF
Comprehensive LEFt Atrial Appendage Occlusion With Rhythm Restoration
The objective of this clinical investigation is to evaluate the feasibility, safety, and effectiveness of a concomitant procedure involving the Volt PFA System and Amulet 2 device in patients indicated for both AF ablation and…
- Conditions
- Atrial Fibrillation (AF), Paroxysmal AF, Persistent Atrial Fibrillation
- Trial name
- CLEAR (NCT07523620)
- Testing
- PVI Ablation, Left Atrial Appendage Occluder Implant
- Where
- 16 sites in Belgium, Czechia and 8 more
- Volunteers
- 240 people
- Sponsor
- Abbott Medical Devices
Anticoagulation
Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy
To quantify rates of bleeding events and investigate the characteristics of prescribed patients, rates of bleeding events, persistence and healthcare resource utilization of Oral Anticoagulants (OACs) prescribed in routine…
- Trial name
- RE-FIT (NCT02921126)
- Where
- Italy
- Volunteers
- 9,914 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Paroxysmal Atrial Fibrillation
Atrial fibrillation is the most common serious abnormal heart rhythm affecting about 2% to 3% of the population, being associated with a 1.5- to 1.9-fold higher risk of death.
- Trial name
- NCT02614521
- Testing
- pulmonary veins ablation's successful outcome
- Where
- Greece
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Non-Valvular Atrial Fibrillation (NVAF)
A Study Evaluating the Associations Between Clinical Characteristics and Use of Oral Anticoagulants in Italian Elderly Participants With Non-Valvular Atrial Fibrillation
The purpose of this study is to provide real-world data useful to address the factors associated to the administration of oral anticoagulants in the elderly population affected by non-valvular atrial fibrillation (NVAF), in…
- Trial name
- PRESBUS (NCT05232643)
- Where
- Italy
- Volunteers
- 636 people
- Sponsor
- Bristol-Myers Squibb